Aditya Infotech IPO comprises a fresh issue of 7.4 million equity shares and an OFS of 11.9 million equity shares ...

The biggest threat to one's wealth isn't market volatility — it's the silent army of fees that compound against us ...

The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial.

Bonds are gaining traction among retail investors in India. Vineet Agarwal of Jiraaf highlights the shift towards fixed ...

JBBB ETF offers 8.04% yield, low correlation, and credit enhancements. A top choice for income-focused portfolios and ...

Global trading giant Jane Street is preparing a defence to SEBI’s market manipulation allegations, claiming its massive India trades were driven by soaring retail demand. As the regulator investigates ...

The public issue will open for all investors on July 29, and the close on July 31, with price band of Rs 640-675 per share ...